A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 420 participants.
Also called NCT05515393
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 420 participants
- Registry
-
NCT05515393
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05515393. Randomized; triple masking; primary purpose treatment. Start 2022-09-24 (actual); primary completion 2023-12-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
- Acronym
- XY03-EA
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- XY03-EA
- Intervention (Drug)
- XY03-EA Placebo
- Lead sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
- Collaborator
- First Affiliated Hospital, Sun Yat-Sen University
Record details
- Record id
cardio:ct-nct05515393- Content hash
90b695ab9185862d8ee4ac27c03961cf3fc0c335e0670e5ef1cc830895f08e99